Novartis AG Debt to Equity Ratio 2006-2019 | NVS

Current and historical debt to equity ratio values for Novartis AG (NVS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Novartis AG debt/equity for the three months ending September 30, 2019 was 0.42.
Novartis AG Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2019-09-30 $21.83B $52.60B 0.42
2019-06-30 $22.12B $51.50B 0.43
2019-03-31 $22.89B $47.31B 0.48
2018-12-31 $22.47B $78.69B 0.29
2018-09-30 $22.61B $78.02B 0.29
2018-06-30 $22.76B $76.90B 0.30
2018-03-31 $23.20B $71.21B 0.33
2017-12-31 $23.22B $74.23B 0.31
2017-09-30 $23.16B 0.00
2017-06-30 $23.00B 0.00
2017-03-31 $22.93B 0.00
2016-12-31 $17.90B 0.00
2016-09-30 $18.26B $75.07B 0.24
2016-06-30 $16.28B $72.53B 0.22
2016-03-31 $16.47B $71.89B 0.23
2015-12-31 $16.33B $77.12B 0.21
2015-09-30 $13.41B $76.79B 0.18
2015-06-30 $13.30B $78.83B 0.17
2015-03-31 $14.83B $76.44B 0.19
2014-12-31 $13.80B $70.84B 0.20
2014-09-30 $12.67B 0.00
2014-06-30 $12.87B 0.00
2014-03-31 $15.20B 0.00
2013-12-31 $11.24B $74.47B 0.15
2013-09-30 $11.12B 0.00
2013-06-30 $11.62B 0.00
2013-03-31 $11.61B 0.00
2012-12-31 $13.78B $69.26B 0.20
2012-09-30 $15.82B $67.21B 0.24
2012-06-30 $13.75B $64.24B 0.21
2012-03-31 $13.90B $63.20B 0.22
2011-12-31 $13.86B $65.94B 0.21
2011-09-30 $13.74B 0.00
2011-06-30 $13.92B 0.00
2011-03-31 $14.53B 0.00
2010-12-31 $14.36B $69.77B 0.21
2010-09-30 $14.33B 0.00
2010-06-30 $13.24B 0.00
2010-03-31 $13.45B 0.00
2009-12-31 $8.68B $57.46B 0.15
2009-09-30 $8.71B 0.00
2009-06-30 $9.20B 0.00
2009-03-31 $6.98B 0.00
2008-12-31 $2.18B $50.44B 0.04
2008-09-30 $2.06B 0.00
2008-06-30 $2.17B 0.00
2008-03-31 $0.75B 0.00
2007-12-31 $0.68B $49.40B 0.01
2007-09-30 $0.67B 0.00
2007-06-30 $0.63B 0.00
2007-03-31 $0.66B 0.00
2006-12-31 $0.66B $41.29B 0.02
2006-09-30 $1.96B 0.00
2006-06-30 $1.62B 0.00
2006-03-31 $1.34B 0.00
2005-12-31 $1.32B $33.16B 0.04
2005-09-30 $2.44B 0.00
2005-06-30 $2.49B 0.00
2005-03-31 $2.59B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $212.060B $51.900B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.778B 16.02
Roche Holding AG (RHHBY) Switzerland $262.948B 0.00
Merck (MRK) United States $225.880B 17.50
Pfizer (PFE) United States $212.068B 12.60
Novo Nordisk (NVO) Denmark $134.242B 23.14
AbbVie (ABBV) United States $127.829B 10.02
AstraZeneca (AZN) United Kingdom $125.337B 22.64
Eli Lilly (LLY) United States $115.446B 21.32
GlaxoSmithKline (GSK) United Kingdom $113.811B 13.78
Sanofi (SNY) France $113.437B 13.94
Bristol-Myers Squibb (BMY) United States $99.843B 13.96
Bayer (BAYRY) Germany $70.967B 10.51
H Lundbeck (HLUYY) Denmark $7.627B 11.01